New J&J CEO Gorsky wants to grow device business | Wall Street Beat

MassDevice.com Wall Street Beat

When Alex Gorsky takes the helm at Johnson & Johnson (NYSE:JNJ) tomorrow, he’ll become responsible for a company bedeviled by a series of high-profile, big-ticket recalls, a more than $1 billion legal settlement – and blessed with the world’s largest medical device business.

In his first public comments ahead of replacing Bill Weldon as CEO, Gorsky told Bloomberg that he plans to make that business even bigger, using some of the $14 billion in cash at his disposal to expand J&J’s footprint in med-tech.

Sign up to get our free newsletters delivered straight to your inbox

Saying there’s value in being a diversified conglomerate, Gorsky told the news service that he has no plans to emulate rival Abbott (NYSE:ABT), which is in the process of carving out its research pharmaceuticals business into a separate firm called AbbVie. The focus at J&J under his watch will be on growth, especially in emerging markets like China, he said.

"We are committed to being diversified across the whole health-care continuum," Gorsky said. "When there are large opportunities that we think can give us some strategic advantage, we will obviously take a look."

As for those recalls, including the shelving of J&J’s DePuy ASR hip implant – which is shaping up to be the most expensive recall ever, with about 6,000 lawsuits filed so far – the new CEO said he’ll work to get the recalled metal-on-metal hip devices and over-the-counter drugs back on the market as soon as possible. Changes are already afoot to address the problems, he said, but declined to go into detail, according to Bloomberg.

"We realize we have a lot of work to do, but the most important thing we think we can do is get the products back on the shelf," Gorsky said. "We know we are going to have to win the hearts and minds and pocketbooks of the consumer."

"I don’t think the company is so broken that it needs to be completely repaired," Thrivant Financial for Lutherans portfolio manager David Heupel told the news service. "A lot of the elements you need for improvement are there. It’s just an execution issue."

 Fitch holds steady on J&J’s long-term debt
Fitch Ratings affirmed J&J’s long-term "AAA" debt ratings and removed its "Negative Rating Watch." Read more

 Accuray deepens its stake in Compact Particle Acceleration
Accuray (NSDQ:ARAY) said it added to its stake in a development-stage company it bought into when it acquired rival TomoTherapy last year for $277 million.

Established in 2008 by TomoTherapy, Compact Particle Acceleration Corp. is working on a compact proton therapy system for cancer. Accuray said it dropped $1.1 million in cash on CPAC April 20 in return for equity and warrants. Including the conversion of a bridge loan worth about $1.3 million, Accuray now owns about 16.3% of CPAC and could further boost that stake to 19%.
Read more

 Arrhythmia Research gets de-listing notice
Arrhythmia Research Technology (NYSE:HRT) said the New York Stock Exchange’s AMEX exchange warned of a possible de-listing due to its failure to file an annual report on time. The exchange gave the company until May 1 to submit a compliance plan, but Arrhythmia Research might have gotten off the hook today, when it released its 2011 earnings report. 
Read more

 CorMedix does too

Arrhythmia Research wasn’t the only publicly traded device maker to run afoul of is exchange’s rules. CorMedix (NYSE:CRMD)
said the NYSE’s Amex market warned it could get the boot, too, unless it submits a compliance plan by May 21 to rectify "losses in 2 of its most recent fiscal years with equity below $2 million."
Read more

 Gabelli slashes stake in Zoll
Über-investor Mario Gabelli, who boosted his stake in Zoll Medical (NSDQ:ZOLL), shortly after it received a $2.21 billion cash offer from Asahi Kasei Corp. (TYO:3407), slashed his holdings in the AED maker from 6.7% to less than 1%.
Read more

 Funding Roundup

 Analysts’ ups and downs

  • 3M Co. (NYSE:MMM): UBS raises estimates, boosts price target to $100, maintains "buy" rating; Goldman Sachs increases price target from $87 to $90, maintains "sell" rating; Jefferies & Co. increases price target from $102 to $108, maintains "buy" rating.
  • C.R. Bard (NYSE:BCR): Leerink Swann maintains "market perform" rating.
  • Cynosure (NSDQ:CYNO): Needham & Co. re-affirms "buy" rating.
  • Edwards Lifesciences (NYSE:EW): Canaccord Genuity reinforces "buy" rating, $86 price target.
  • Integra LifeSciences (NSDQ:IART): Bank of America raises price target from $26 to $36.
  • Intuitive Surgical (NSDQ:ISRG): Zacks Equity Research upgrades to "outperform," sets $701 price target; Raymond James upgrades to "outperform."

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply